Comparative Pharmacology
Head-to-head clinical analysis: LOTRISONE versus OPTOMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LOTRISONE versus OPTOMYCIN.
LOTRISONE vs OPTOMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Optomycin is a semi-synthetic glycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, preventing transpeptidation and cross-linking.
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
1.5 mg/kg IV every 8 hours; alternatively, 5-7 mg/kg IV daily.
None Documented
None Documented
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
3-5 hours (terminal half-life); prolonged to 10-20 hours in renal impairment.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Renal: 75-90% unchanged; biliary: 5-10%; fecal: <5%.
Category C
Category C
Topical Antifungal/Corticosteroid Combination
Ophthalmic Antibiotic/Corticosteroid Combination